Tags : Juno

PharmaShots Weekly Snapshot (March 16-20, 2020)

1. Merck Collaborates with Dragonfly to Develop and Commercialize Novel Therapies Utilizing TriNKET Platform Published: Mar 19, 2020 | Tags: Merck, Collaborates, Dragonfly, Develop, Commercialize, Novel Therapies, Utilizing, TriNKET Platform 2.  BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US Published: Mar 20, 2020 | Tags: BGI, Reports, Availability, RT-PCR, SARS-CoV-2 […]Read More

PharmaShots’ Most Read News of 2019

The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list of 20 most read life sciences news on PharmaShots in 2019. 1. Celltrion Signed an Exclusive Co-Marketing Agreement with Juno in Australia Juno provided sales […]Read More

Celltrion Signs an Exclusive Co-Marketing Agreement with Juno in Australia

Shots: Juno to provide sales promotion and hospital contracting services to Australian Hospital market customers and will co-market Herzuma (biosimilar, trastuzumab) and Truxima (biosimilar, rituximab) with Celltrion in Australia  The focus of the agreement is to market globally biosimilar brands to Australian Healthcare professionals and patients Herzuma (CT-P6, biosimilar, trastuzumab) is a mAb targeting the […]Read More

Celgene to Acquire Juno for its Cellular Immunotherapy & Hematology

Shots: Celgene acquires Juno, in all stock transaction with its JCAR017& JCARH125 clinical products. Juno to receive $87/share in cash, making total deal value as $9B The focus of the agreement is to develop drugs in fields of oncology and hematology with Juno’s cellular immunotherapy platform and research capabilities JCAR017 (lisocabtagene maraleucel; liso-cel) is a […]Read More